Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis.

Allard B, Cousineau I, Allard D, Buisseret L, Pommey S, Chrobak P, Stagg J.

Oncoimmunology. 2019 Apr 26;8(8):1601481. doi: 10.1080/2162402X.2019.1601481. eCollection 2019.

PMID:
31413909
2.

WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors.

Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, Azzi F, Pommey S, Do KA, Saad F, Trudel D, Young M, Stagg J.

Oncoimmunology. 2019 Mar 22;8(5):e1581545. doi: 10.1080/2162402X.2019.1581545. eCollection 2019.

PMID:
31069142
3.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J.

Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.

4.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

5.

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J.

Cancer Res. 2017 Jan 15;77(2):312-319. doi: 10.1158/0008-5472.CAN-16-1873. Epub 2016 Nov 21.

6.

Evaluation of CD4+ CD25+/- CD39+ T-cell populations in peripheral blood of patients following kidney transplantation and during acute allograft rejection.

McRae JL, Chia JS, Pommey SA, Dwyer KM.

Nephrology (Carlton). 2017 Jul;22(7):505-512. doi: 10.1111/nep.12894.

PMID:
27517975
7.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J.

Cancer Res. 2015 Nov 1;75(21):4494-503. doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11.

8.

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.

Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J.

Clin Cancer Res. 2016 Jan 1;22(1):158-66. doi: 10.1158/1078-0432.CCR-15-1181. Epub 2015 Aug 7.

9.

The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.

Spring K, Fournier P, Lapointe L, Chabot C, Roussy J, Pommey S, Stagg J, Royal I.

Oncogene. 2015 Oct 29;34(44):5536-47. doi: 10.1038/onc.2015.9. Epub 2015 Mar 16.

PMID:
25772245
10.

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Allard B, Pommey S, Smyth MJ, Stagg J.

Clin Cancer Res. 2013 Oct 15;19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. Epub 2013 Aug 27.

11.

Anti-CD73 therapy impairs tumor angiogenesis.

Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J.

Int J Cancer. 2014 Mar 15;134(6):1466-73. doi: 10.1002/ijc.28456. Epub 2013 Sep 18.

12.

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6. doi: 10.1073/pnas.1222251110. Epub 2013 Jun 17.

13.

Liver grafts from CD39-overexpressing rodents are protected from ischemia reperfusion injury due to reduced numbers of resident CD4+ T cells.

Pommey S, Lu B, McRae J, Stagg J, Hill P, Salvaris E, Robson SC, d'Apice AJ, Cowan PJ, Dwyer KM.

Hepatology. 2013 Apr;57(4):1597-606. doi: 10.1002/hep.25985. Epub 2013 Mar 14.

PMID:
22829222
14.

Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype.

Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, Winterhalter A, Doherty G, Deaglio S, Koulmanda M, Gao W, Robson SC, Strom TB.

Am J Transplant. 2010 Nov;10(11):2410-20. doi: 10.1111/j.1600-6143.2010.03291.x.

15.

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52. doi: 10.1073/pnas.0908801107. Epub 2010 Jan 4.

16.

Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.

Stagg J, Sharkey J, Pommey S, Young R, Takeda K, Yagita H, Johnstone RW, Smyth MJ.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16254-9. doi: 10.1073/pnas.0806849105. Epub 2008 Oct 6.

17.

Production of homozygous alpha-1,3-galactosyltransferase knockout pigs by breeding and somatic cell nuclear transfer.

Nottle MB, Beebe LF, Harrison SJ, McIlfatrick SM, Ashman RJ, O'Connell PJ, Salvaris EJ, Fisicaro N, Pommey S, Cowan PJ, d'Apice AJ.

Xenotransplantation. 2007 Jul;14(4):339-44.

PMID:
17669176
18.

[The use of mesenchymal stromal cells in oncology and cell therapy].

Pommey S, Galipeau J.

Bull Cancer. 2006 Sep;93(9):901-7. Review. French.

19.

Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell.

Stagg J, Pommey S, Eliopoulos N, Galipeau J.

Blood. 2006 Mar 15;107(6):2570-7. Epub 2005 Nov 17.

PMID:
16293599
20.

Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice.

Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J.

Blood. 2005 Dec 15;106(13):4057-65. Epub 2005 Aug 23.

PMID:
16118325

Supplemental Content

Loading ...
Support Center